Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value per share
-
Shares outstanding
-
75.9M
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
66.1M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$1.89B
-
Value change
-
+$283M
-
Put/Call ratio
-
0.17
-
Number of buys
-
86
-
Number of sells
-
-43
-
Price
-
$28.68
Significant Holders of CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) as of Q4 2024
159 filings reported holding CGON - CG Oncology, Inc. - Common stock, $0.0001 par value per share as of Q4 2024.
CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.1M shares
of 75.9M outstanding shares and own 87.09% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (6.37M shares), VANGUARD GROUP INC (5.86M shares), BlackRock, Inc. (4.06M shares), TCG Crossover Management, LLC (3.67M shares), BRAIDWELL LP (3.28M shares), Kynam Capital Management, LP (2.52M shares), FMR LLC (2.43M shares), Foresite Capital Management VI LLC (2.22M shares), STATE STREET CORP (1.92M shares), and WELLINGTON MANAGEMENT GROUP LLP (1.91M shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.